National Science Foundation

Remedium Bio is a Boston-based gene therapy company dedicated to developing curative treatments for various debilitating conditions. The company employs a modular approach to research and development, utilizing established technologies in innovative ways to address well-understood disease mechanisms. By focusing on clinically validated molecules and targeted treatment strategies, Remedium Bio aims to create effective therapies for conditions within rheumatology, endocrinology, and neurology. Its pipeline includes promising gene therapy candidates designed to tackle a wide range of diseases, including immune and age-related disorders.

Sharper Sense is a company focused on wearable neurotechnology designed to enhance sensory acuity, including vision, hearing, and touch. The firm has developed a neuromodulation patch that employs comfortable, noninvasive electrical stimulation to improve sensory processing. This technology has both clinical and commercial applications, particularly in treating sensory processing disorders and sensory loss. By enhancing performance and safety, Sharper Sense aims to provide users with a clearer and more accurate perception of their surroundings.

Bespoke Biotherapeutics provides an effective natural immune response and overcomes the limitations of currently approved immunotherapies against cancer by inventing novel, customised living drugs called engineered B-cell therapeutics. They offer customised B-cell sourcing, isolation, activation, culture expansion, and non-viral genetic engineering methodologies uniquely suited to optimise commercial B-cell products for infusion.

Tiny Cargo specializes in a unique drug delivery system utilizing non-immunogenic bovine milk-derived exosomes. This innovative approach allows for the effective oral or intravenous administration of potent therapeutics. The company focuses on delivering treatments for various serious health conditions, including ischemic heart disease, gastrointestinal radiation disease, and glioblastoma multiforme, among others. By leveraging its technology, Tiny Cargo aims to enhance the delivery of peptide drugs, making it applicable to a wide range of current peptide therapeutics and improving patient outcomes in the treatment of neurological and other pathologies.

OncoSTING, located in Baltimore, is developing novel bladder cancer therapies that work by combining the potency of standard BCG immunotherapy with long-lived delivery of potent STING agonists. (JHU)

Oculogenex is a biopharmaceutical company that specializes in gene therapy for the treatment of retinal disorders. The company was founded in 2020 and is headquartered in La Habra, California.

Oxalo Therapeutics is focused on developing innovative drug therapies aimed at treating rare kidney diseases and preventing recurring kidney stones. The company specifically targets primary hyperoxaluria and other oxalate-related pathologies through a novel approach that utilizes a gut bacterium to facilitate the safe removal of oxalate from the body. By mimicking natural mechanisms, Oxalo Therapeutics seeks to provide effective treatment options for patients suffering from conditions associated with high levels of oxalate, thereby improving their quality of life and reducing the incidence of kidney stone recurrence. The company's expertise in the microbiome and translational research underpins its commitment to advancing early-stage technology in the field of kidney health.

Creative BioTherapeutics is a biotechnology company dedicated to developing innovative therapies for cancer and viral diseases. The company aims to transform cancer and viral disease research by targeting the fundamental issues of immune evasion and drug resistance. With a focus on recurrent and drug-resistant cancers, Creative BioTherapeutics is creating first-in-class biologics designed to address critical needs in treatment, particularly for patients with recurrent metastatic breast cancer. This approach not only seeks to enhance tumor regression but also holds the potential for cures in both adult and childhood cancers, thereby improving treatment options for patients facing these challenging conditions.

Simmbion specializes in innovative therapeutic solutions by utilizing symbionts to manufacture therapeutic agents directly within the human body, effectively transforming it into a living pharmacy. This technology aims to eliminate the challenges associated with traditional therapy manufacturing, such as the need for complex production processes, repeated injections, and temperature-sensitive storage. By providing a single injection that lasts up to 12 weeks, Simmbion's approach addresses supply chain disruptions and enhances affordability and accessibility of cell therapies for diverse patient populations. Their adaptable and universally immune compatible systems focus on delivering biological drugs directly in vivo, supporting a patient-centric and outcome-driven healthcare model while minimizing the risks of infections and immune rejection.

Iaso Therapeutics, founded in 2018 and based in East Lansing, Michigan, is a biotechnology company focused on developing vaccines aimed at improving human health and treating infectious diseases. The company’s platform is dedicated to creating vaccines for serious illnesses, including smallpox, yellow fever, and tetanus. By providing healthcare professionals with innovative technologies, Iaso Therapeutics seeks to enhance public health outcomes and address critical health challenges.

Hypersound Medical provides neuromodulatory methods using neurostimulation principles. They concern peripheral nerve stimulation, spinal cord stimulation, deep brain stimulation, motor cortex stimulation, and repetitive transcranial magnetic stimulation.

Acrigen Biosciences is dedicated to making gene editing safe. It develops technologies to improve efficiency and enhance the safety of CRISPR-Cas based gene editing. CRISPR-Cas system which enables the precise enzymatic editing of genes is one of the most exciting and promising techniques to be developed in the last few years with the capability to prevent or cure many devastating diseases. It was founded in 2019 and is headquartered in Berkeley, California.

WIndow Therapeutics discovers and develops transformational therapeutics to address critical unmet patient needs in cancer and other life-threatening diseases. They develop breakthrough cancer therapeutics designed to penetrate and permeate into diseased tissue and exert activity specifically against cancer cells and not healthy ones.

Amphix Bio is engaged in the development of advanced therapeutic materials aimed at regenerative medicine. The company specializes in creating nanofiber materials that replicate the structure and dynamic characteristics of human tissues. By integrating biological signals, these materials instruct cells to activate regenerative processes. Amphix Bio's innovations enable the development of therapies designed to repair a variety of tissues, including bone, cartilage, muscle, cardiovascular tissues, and the brain and spinal cord. The promising results observed in both preclinical and clinical trials highlight the potential of Amphix Bio's approach in transforming therapeutic applications in medicine.

Nostopharma specializes in developing treatments for pathologic bone growth, aiming to prevent rare bone diseases and minimize complications from traumatic injuries. The company offers a nanoparticle drug delivery system that addresses soft tissue trauma complications, facilitating the formation of new bone after surgeries, burns, and other traumatic incidents. By enhancing the recovery process, Nostopharma's innovative approach supports healthcare providers in improving clinical outcomes for patients undergoing surgical procedures related to post-traumatic injuries. Additionally, the company's efforts contribute to reducing rehabilitation costs for society.

Isolere Bio is a biotechnology company dedicated to simplifying the purification of biotherapeutics, particularly monoclonal antibodies and Adeno-Associated Viruses (AAV). Co-founded with the aim of enhancing global access to essential drugs, Isolere Bio develops innovative manufacturing technologies that utilize a straightforward Tangential Flow Filtration (TFF) setup. This approach facilitates a seamless transition from laboratory-scale processes to large-scale industrial production, thereby improving efficiency within the bioprocessing industry. As monoclonal antibodies continue to gain prominence as effective therapeutics and important research tools, Isolere Bio's work plays a crucial role in advancing the development of new diagnostics and treatments.

Auctus Biologics is a pre-clinical biotechnology company that develops antibody mimetics for therapeutic and diagnostic applications.Antibodies are the most prolific biologics in clinical environments because of their ability to bind targets with high affinity and specificity. However, antibodies also carry liabilities. They are often unstable and require costly cold-chain management to reach their destinations in active form. Because of their fragility, antibodies typically cannot be used in extreme environments like the gastrointestinal tract and can require lengthy infusions to administer to patients.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Vulcan Biologics is a biotechnology company based in Irvine, California, established in 2019. It specializes in the modulation of the microbiome through the use of bacteriophages, which are viruses that specifically infect bacteria without harming human cells. This innovative platform aims to achieve stable and persistent changes in the gut microbiome, facilitating the treatment of gluten-related disorders such as gluten sensitivity and celiac disease. By altering the composition of gut bacteria, Vulcan Biologics enables healthcare providers to offer targeted therapeutic solutions for individuals affected by these conditions.

Astek Diagnostics is focused on developing a precision diagnostic platform that assists physicians in prescribing appropriate antibiotics for patients suffering from bacterial sepsis within one hour. The company’s technology utilizes a single-use cartridge to rapidly detect bacterial infections in urine by measuring the oxygen consumption of various bacterial species. This innovative approach not only speeds up the identification process but also aids in combating antibiotic resistance through effective susceptibility testing.

Akttyva Therapeutics specializes in the development of targeted therapeutics aimed at addressing cell barrier dysfunction associated with various vascular disorders. The company leverages a deep understanding of biological pathways, along with advanced artificial intelligence and machine learning techniques, to design solutions that enhance the treatment of these conditions. Through its innovative approach, Akttyva Therapeutics seeks to provide healthcare professionals with effective tools to manage and treat disorders related to cell barriers.

Averto Medical is a manufacturer of medical devices focused on addressing gastrointestinal diseases. The company specializes in developing innovative solutions designed to facilitate minimally invasive colorectal tumor removal, which aims to reduce the need for multiple surgical procedures and associated complications. By providing effective medical care options for patients suffering from gastrointestinal disorders, Averto Medical seeks to improve patient outcomes and streamline treatment processes in this critical area of healthcare.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Felix Biotechnology is working to accelerate the deployment of novel biotherapeutics to manage infectious diseases. Felix Biotechnology's bio-therapeutics targets antibiotic-resistant bacteria to manage infectious diseases precisely and effectively, allowing healthcare professionals to manage urgent microbial challenges in human health.

Niche Biomedical is a platform and therapy development firm that specializes in creating innovative solutions for chronic injuries and disorders that have not responded to traditional pharmacological treatments. The company has developed ANEUVO®, which focuses on addressing these challenging medical conditions. Among its notable innovations is ExaStim®, a non-invasive neuromodulation system that has received FDA Breakthrough Device Designation for the treatment of spinal cord injuries. Additionally, Niche Biomedical is advancing a gastrointestinal therapeutic device aimed at alleviating postoperative ileus and restoring gastrointestinal motility. This device leverages bioelectronic medicine to revolutionize treatment options for various diseases and injuries that are difficult to manage with conventional pharmaceuticals. The company is also capable of developing miniaturized implantable devices that maintain sophisticated functionality, allowing for targeted neuromodulation therapies.

TheraCea Pharma is a biotechnology company based in Tucson that focuses on developing precision medicine for individuals with neurological disorders. As a spin-off from the University of Arizona, the company has developed and licensed advanced radiochemistry technology that enables efficient and rapid fluorine-18 radiolabeling of biomolecules. This innovative approach supports both clinical and research applications, particularly in the context of neurological conditions. TheraCea Pharma's treatments aim to counteract dyskinesia, a side effect commonly associated with L-dopa, the standard treatment for Parkinson's disease. By providing new diagnostic agents, the company enhances medical professionals' capabilities in detecting not only neurological disorders but also cancer, thereby contributing to improved healthcare outcomes.

TRGel, founded in 2010 and located in Irvine, California, specializes in the development of glucose-based biopolymers designed to serve as an alternative to calcium alginate for encapsulation purposes. The company’s biopolymers are crafted from biocompatible materials, which encompass thermoresponsive hydrogels with adjustable gelation temperatures. These innovative biopolymers enable researchers to utilize them effectively as vehicles for drug delivery, expanding the possibilities for applications in various fields.

Kodikaz goal is to move from incremental cancer therapies with devastating side effects to durable cures through targeted therapies that can eradicate cancers. Zip-Code™ Technology platform is a first-in-class, cell-specific delivery system that can be used for a broad range of gene therapy applications. Because the Zip-Codes ™ is derived from an endogenous human mechanism it avoids all of the challenges of viral delivery approaches. The Zip-Codes ™ are universally applicable and specific for each cell type.

ZelosDx specializes in the development of blood testing products aimed at advancing research in brain health and diseases. The company provides researchers with access to proprietary technology that can be licensed and adapted for blood testing kits and automated laboratory equipment. Additionally, it offers pharmaceutical collaborators biomarker technology to support drug discovery efforts. By delivering critical data for diagnosis, monitoring, and evaluating therapeutic responses, ZelosDx facilitates significant advancements in the understanding and treatment of brain-related conditions.

Nano PharmaSolutions specializes in enhancing the bioavailability of insoluble drugs through its proprietary nanoformulation technology. The company has developed an innovative phase-transition technology platform that significantly improves the solubility of BCS 2 and BCS 4 active pharmaceutical ingredients (APIs) without the need for excipients, which are typically used in traditional processes like spray-dry dispersion and emulsification. By vaporizing the API and depositing it onto a carrier molecule, Nano PharmaSolutions enables the production of nanoparticles that can be processed into various dosage forms. Additionally, the company focuses on delivering neurodegenerative therapeutics directly to the brain via an intranasal route, facilitating a rapid onset of action and enhancing safety profiles. Their pipeline includes treatments for conditions such as Parkinson's disease, peripheral neuropathy, and substance abuse disorders, positioning Nano PharmaSolutions as a key player in the field of nanomedicine.

Theromics Inc. is a biotechnology company focused on developing innovative cell therapies, particularly in the field of thermal ablation for cancer treatment. Founded in 2016 and based in West Bridgewater, Massachusetts, the company has created HeatSYNC Gel, a biopolymer thermal accelerant designed to enhance the effectiveness of microwave and radiofrequency ablation procedures. This gel improves the delivery and absorption of thermal energy in soft tissue and bone, optimizing the ablation zone's shape and volume. By increasing local tissue electrical conductivity, HeatSYNC Gel helps to prevent heat loss due to blood flow, allowing for more precise targeting of tumors and protecting surrounding healthy tissue. The gel can be administered through various methods, including syringe, laparoscope, and bronchoscope, and is intended to improve the overall efficacy of thermal ablation therapies while enabling personalized treatment approaches.

SingletO2 Therapeutics creates new treatments for periodontal disease using singlet oxygen. The company was founded in 2015 and is headquartered in New Providence, New Jersey.

MedChem Partners is a medicinal chemistry CRO that specializes in developing small molecule therapeutics. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.

Drive Therapeutics is a new biotechnology company that strives to improve treatment for retinal diseases.

Paramita Therapeutics is a biotech company established in 2018 and based in San Diego, California. The company is dedicated to developing innovative therapeutics for cancer and infectious diseases. It specializes in efficiently transitioning new therapeutics into clinical settings using a patented, multifunctional chemical platform. This approach allows Paramita Therapeutics to create multivalent drug conjugates derived from recognized and approved molecules with established safety and toxicology profiles. By leveraging its expertise, the company aims to provide patients with access to effective cancer treatments and dual-function therapeutic and vaccine products.

ALSUS MEDICAL offers treatment for urinary stream problems that may be weak or stop and start. In some cases, it can lead to infection, bladder stones, and reduced kidney function. They offer treatments that include medication that relaxes or shrinks the prostate, surgery, and minimally invasive surgery.

InSoma Bio integrates biology and materials science to solve problems in tissue engineering and regenerative medicine. It offers genetically engineer protein-based materials that can mimic the naturally found elastin found in extracellular tissues. The company also offers reconstructive plastic surgeries and injectable materials.

Cordance Medical is a medical device company that develops radical therapy for a variety of CNS pathology, including primary and metastatic cancer, Alzheimer's, and Parkinson's diseases.

Avior Bio is a clinical-stage, pharmaceutical company developing drugs for distressed neurological conditions. Using its disruptive drug delivery technology – Speedit™ Transmucosal Film Technology – we are positioned to develop products that bring unsurpassed value in efficacy and safety. Avior has an excellent management team, a strong advisory board, supportive partners, dedicated scientists, and knowledgeable clinicians that position us to be successful.

Tacit Therapeutics created RNA-targeting treatments for devastating diseases. By repurposing pre-existing components of human cells, we have created the first broadly applicable and inherently non-immunogenic means to repair mutated genes. The company was founded in 2021 and is based in South San Francisco, California.

Verantos is the market leader in high-validity real-world evidence for life sciences. By incorporating robust clinical narrative data, artificial intelligence technology, and measured validity, Verantos is the first company to generate research-grade evidence at scale across all therapeutic areas. The Verantos Evidence Platform integrates heterogeneous real-world data sources and generates evidence with the accuracy necessary for market access, HEOR, medical affairs, and regulatory use.

Partillion Bioscience is an early-stage life science company focused on developing a functional single-cell analysis platform. This innovative platform utilizes a novel nano vial technology to rapidly compartmentalize and analyze millions of single cells, specifically targeting secreted proteins. By enabling detailed examination of biological functions, Partillion aims to democratize advanced single-cell assays for biotech laboratories and clients. This capability supports the development of more effective therapies for various conditions, including cancer, autoimmune diseases, and infectious diseases.

SpheroFill is a drug delivery platform capable of protecting, delivering, and releasing API as solid, liquid, or even gas. From improved compliance by reducing dose frequency to enabling oral formulations that are not possible with present technology, these glass microspheres are the future of drug delivery.

Current Surgical is a surgical device company founded in 2020 and headquartered in Washington, DC. The company specializes in developing advanced tools aimed at the treatment of solid tumors. Its flagship product is a smart surgical needle designed for minimally invasive tumor detection and ablation. This innovative needle utilizes real-time X-ray guidance and ultrasound energy to effectively heat and destroy tumors while preserving surrounding vital organs and tissue. By enabling surgeons to target tumors located near critical anatomy, Current Surgical aims to enhance surgical precision and improve patient outcomes.

Galaxy Therapeutics provides neurovascular devices that increase the rate of curing the disease and offer easy deployment, fluoroscopic visualization, and treatment for shallow or large aneurysms, enabling patients to avail improved medical treatment.

Infini Fluidics develops injectable drug delivery systems intended to treat diseases such as cancer and cardiovascular disease. They provide injectable drug delivery systems at an industrial scale on a portable chip, combining microfluidics with semiconductor technology, enabling patients, healthcare providers, and facilities to get access to lifesaving drugs.

FluidForm Bio is a biotechnology company focused on creating living human tissue to enhance disease treatment. Utilizing its patented FRESH technology, the company specializes in 3D bioprinting, which enables the production of high-quality tissue that mimics real human tissue by integrating cells and proteins without additional materials. This innovative platform allows for the design and fabrication of complex tissue structures with embedded vasculature and multiple materials within a single print. Through collaborations with leading life science companies, FluidForm Bio's technology has been validated for various applications, paving the way for novel therapeutic programs in the healthcare sector. Founded in 2018 and headquartered in Waltham, Massachusetts, FluidForm Bio aims to provide better treatment options for patients through its transformational approach to tissue engineering.

Oculogenex is a biopharmaceutical company that specializes in gene therapy for the treatment of retinal disorders. The company was founded in 2020 and is headquartered in La Habra, California.

Enable Therapeutics is a biotechnology company developing a patented drug delivery platform. The company was founded in 2020 and is headquartered in Hopedale, Massachusetts.

Amberstone Biosciences discovers novel immunotherapies through innovative technologies and creative partnerships. Amberstone's focus is difficult targets requiring a unique mode-of-action and/or particular functional property, which are otherwise challenging for traditional approaches. These conventional limitations are overcome via a two-pronged approach. First, we have demonstrated success with our microfluidics-powered AmberFlow drug-discovery platform. Second, our team of experts has keen insights in immuno-oncology and ample experience with single-cell assay biology.

Produces kits for protein sample preparation to enable better drug and biomarker discovery. vision is to be the leader of protein sample preparation, enabling the discovery of important therapeutics and diagnostics and bringing them to market faster than ever before.

Nabla Bio operates an autoreverse platform that facilitates the rapid discovery of novel protein variants with unique properties. By leveraging insights gained from billions of natural proteins, the company engineers these enhanced proteins for both medical and industrial applications. Through extensive experimentation, Nabla Bio develops new medicines and improves nutritional products, allowing clients to conduct complex measurements of protein function and implement innovative solutions in various fields.

NeyroblastGX is a biotechnology company develops theranostic products to treat neurodegenerative and infectious diseases. The company was founded in 2020 and is headquartered in Murrieta, California.

VeriSIM Life, Inc. is a biotechnology company based in San Francisco, California, that specializes in developing disease-specific biosimulation models to enhance drug development processes. Founded in 2017, the company utilizes its proprietary BIOiSIM platform to predict the clinical outcomes of new drugs prior to clinical trials, thereby replacing traditional animal testing methods. By employing artificial intelligence, VeriSIM Life aims to improve the accuracy and efficiency of drug development, ultimately contributing to personalized healthcare solutions. Their offerings are tailored to meet the needs of both pre-clinical and clinical programs, focusing on small molecules, large molecules, and viruses to facilitate better treatment options and increase human life expectancy.

Florica Therapeutics develops exosome-based therapeutics to extend the life and prevent aging diseases. The company was founded in 2019 and is headquartered in Livermore, California.

Nano RED specializes in precision delivery technologies aimed at advancing RNA and immunotherapeutics for cancer treatment. The company develops innovative immunotherapy solutions that utilize liposomes, which are injected into the bloodstream. This approach allows for the direct release of cancer therapies into tumors and their surrounding environments, while also addressing the associated toxicity within the body. Through its cutting-edge technology, Nano RED seeks to enhance the effectiveness of cancer treatments and improve patient outcomes.

Gradient Medical, founded in 2020 and based in Raleigh, North Carolina, specializes in developing innovative interventional oncology services, specifically focused on ACE therapy. This therapy utilizes electrical pulses designed to target cancer cells and disrupt essential biological functions. By incorporating real-time sensing technology, Gradient Medical provides clinicians with enhanced control over the treatment area, which optimizes therapeutic effectiveness and reduces treatment durations. This approach enables healthcare professionals to effectively treat large, inoperable tumors located near vital structures, addressing a critical need in cancer care.

FibrosIX is a biotechnology company founded in 2016 and based in East Lansing, Michigan. The company focuses on developing small-molecule therapeutics aimed at preventing lung fibrosis in cancer patients. Its drug candidates target a crucial signaling pathway involved in the progression of fibrotic diseases. By doing so, FibrosIX aims to help healthcare providers mitigate issues related to poor lung function and shortness of breath in affected patients.

NeuroDyn develops neurological devices that alleviate seizure activity in children who suffer from congenital brain disease, adults with seizure activity, and veterans who suffer brain damage, enabling the medical community to ensure relief for those who suffer from debilitating seizure effects.

GRI Bio, Inc. is a biotechnology company based in La Jolla, California, focused on developing cell-based therapies for liver diseases and autoimmune disorders. The company's primary program, GRI-0621, is an oral therapeutic designed to inhibit type 1 Natural Killer T (NKT) cells, aiming to restore balance to dysregulated immune responses associated with inflammation and fibrosis. This small molecule acts as a dual agonist of RAR-beta and gamma, promoting immune homeostasis. GRI Bio also explores additional product candidates, including GRI-0803, which targets type 2 NKT cells. Established in 2009, the company is in the clinical stage of development, working to address significant unmet medical needs in the field of immune-mediated diseases.

Spirrow Therapeutics provides lung restoration to babies suffering from ARDS by using new proprietary methods. They provide polymer lung surfactant to low complexity synthesis and formulation, interface affinity exceeds competing agents, reduces alveolar surface tension, and fluid accumulation.

Grit Bio is a biotechnology company founded in 2017 and based in New York, NY, focused on developing cancer therapeutics specifically aimed at pharyngeal squamous cell carcinoma. The company's innovative approach targets the increased turnover of lipid metabolism and the production of oncogenic products associated with sphingolipid metabolism. By addressing these mechanisms, Grit Bio aims to enhance the safety of cancer treatment and extend remission periods for patients.

Progenitor MDX is engaged in developing cellular immunotherapy technologies that facilitate the creation of induced pluripotent stem cells for use in immune-oncology and engineered cell therapies. The company combines all Yamanaka factors into a single vector, enabling simple and reliable cellular reprogramming. This innovation supports the efficient production of allogeneic off-the-shelf CAR constructs derived from various cell sources. In addition to its focus on cellular immunotherapy, Progenitor MDX offers a comprehensive and customizable solution for managing COVID-19 infections, which includes providing testing results and actionable plans for infection management to support community health.

Akanocure Pharmaceuticals is a biotechnology company focused on developing innovative anti-cancer chemotherapeutic drugs aimed at treating various forms of cancer. The company is dedicated to finding therapeutic approaches that effectively block the metastatic processes responsible for 90% of cancer-related deaths. By harnessing the expertise of its team throughout the drug discovery and development phases, Akanocure aims to create novel small molecules derived from natural resources. These bio-targeted therapeutics are designed not only to combat cancer but also to alleviate the side effects associated with chemotherapy and other cancer treatments, ultimately improving the quality of life for patients.

Creative BioTherapeutics is a biotechnology company dedicated to developing innovative therapies for cancer and viral diseases. The company aims to transform cancer and viral disease research by targeting the fundamental issues of immune evasion and drug resistance. With a focus on recurrent and drug-resistant cancers, Creative BioTherapeutics is creating first-in-class biologics designed to address critical needs in treatment, particularly for patients with recurrent metastatic breast cancer. This approach not only seeks to enhance tumor regression but also holds the potential for cures in both adult and childhood cancers, thereby improving treatment options for patients facing these challenging conditions.

Optimeos Life Sciences is a biotechnology company focused on developing advanced drug delivery systems that utilize biologics, peptides, and RNA for disease treatment. The company has created encapsulation technology that enhances the efficacy of these therapeutic agents by protecting them and ensuring their precise delivery to targeted areas within the body. This innovation addresses existing challenges in the field of biologics and peptide therapeutics, facilitating sustained release of these treatments through the use of nano-composite microparticles. By improving the delivery mechanism, Optimeos Life Sciences aims to enhance patient outcomes in the management of various diseases.

Saphtx is a biotechnology company based in Newark, New Jersey, founded in 2018. The company specializes in developing protein-based therapeutic strategies aimed at treating a variety of diseases. Utilizing advanced techniques such as computer-aided lead compound design and screening, natural product discovery, drug repurposing, and combination therapy, Saphtx focuses on creating innovative technologies to address health challenges. Their work includes therapies for COVID-19 and other diseases, enhancing treatment options for patients.

Think Bioscience is focused on advancing synthetic biology to enhance the design and assembly of improved medicines. The company utilizes a unique technology that encodes complex molecular objectives into microbial hosts, facilitating the identification, construction, and evolution of small molecules. This innovative approach allows medical researchers to leverage microbes in the drug discovery process, potentially leading to more effective therapeutic solutions. Through its efforts, Think Bioscience aims to transform how medicines are developed and contribute to the future of healthcare.

TEGA was founded to exploit glycoscience-related technologies for the treatment of life-threatening diseases. Glycans, or complex carbohydrates, play important roles in many physiological and pathophysiological processes, but their value as pharmaceutical targets remains underexploited by industry. TEGA specializes in the science of glycans. The TEGA pipeline includes two major programs: glycoside-enhanced lysosomal delivery of proteins and recombinant production of heparan sulfate and heparin. They aim to improve quality of life for patients by enabling delivery of lifesaving treatments for unmet medical needs. Their work is motivated by a commitment to innovation and helping patients. They combine their powerful insights and rigorous scientific methods to help pharmaceutical companies overcome the obstacle of the blood-brain barrier.

Omnicyte is a biotechnology company that develops targeted treatments for cancer therapy. The company develops a proprietary Immuno-Oncology Platform Technology for recombinant targeted immunomodulators, ovarian cancer indication, small cell lung cancer, and multiple additional indications.

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision’s CLIA-certified, central laboratory in Pittsburgh. Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

ActivSignal is a biotech company that develops protein profiling for diagnostics and other applications. The company was founded in 2016 and is headquartered in Natick, Massachusetts.

Jupiter Therapeutics is a biotechnology company that creates cell-membrane-based therapeutics. The company enables a synthetic biology approach enabling the rapid design and synthesis of a pipeline of assets focused on cancer, autoimmunity, drug delivery, and gene therapy.

Acrigen Biosciences is dedicated to making gene editing safe. It develops technologies to improve efficiency and enhance the safety of CRISPR-Cas based gene editing. CRISPR-Cas system which enables the precise enzymatic editing of genes is one of the most exciting and promising techniques to be developed in the last few years with the capability to prevent or cure many devastating diseases. It was founded in 2019 and is headquartered in Berkeley, California.

Inherent Biosciences is a molecular diagnostics company focused on transforming the trial and error approach in medicine by leveraging insights from epigenetics. The company aims to provide clarity on complex health issues by identifying dysregulation across multiple genes and pathways, which informs personalized treatment strategies. Inherent Biosciences develops innovative therapies for a range of conditions, including pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. By translating biological discoveries into actionable insights, the company seeks to enhance patient care and improve outcomes in various medical fields.

AgThera is a biotechnology company focused on discovering, developing, and commercializing innovative antimicrobial medicines for infectious diseases. The company specializes in advanced probiotics that are engineered to effectively eliminate pathogens, including antibiotic-resistant bacteria. AgThera’s platform utilizes probiotic bacteria that express and secrete antimicrobial peptides, providing a novel approach to combatting infections. The company's research and development efforts are supported by grants from the US National Science Foundation and the US Department of Agriculture, enabling the advancement of its AI-enhanced R&D program. AgThera aims to facilitate the development of drugs for both human and livestock use, addressing the growing concern of antibiotic resistance in various medical and agricultural settings.

VerImmune, based in Baltimore, Maryland, is an immuno-oncology company focused on developing innovative cancer therapies through its proprietary technology, Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs). This unique approach aims to harness pre-existing immune memory from pathogens or childhood vaccines to target and redirect the immune system toward tumors. By doing so, VerImmune seeks to address significant challenges in cancer treatment, particularly for patients with limited options or those who have developed resistance to conventional therapies. The company's strategy promises to offer low toxicity and sustained benefits across a diverse range of cancer types, potentially transforming the treatment landscape for those with difficult-to-treat malignancies.

New Equilibrium Biosciences is focused on developing therapeutic drugs aimed at treating cancer and neurodegenerative diseases. The company employs a unique approach that integrates artificial intelligence with quantum chemistry to enhance biophysical experiments. This innovative platform specializes in the research and development of therapeutics that target intrinsically disordered proteins (IDPs), which are often implicated in various neurodegenerative disorders. By utilizing IDP-specific compound libraries, New Equilibrium Biosciences seeks to identify and exploit transient binding pockets on these proteins, facilitating the discovery of lead drug candidates. This approach aims to improve medical procedures and ultimately contribute to advancements in healthcare.

Vitanova Biomedical is an early-stage biotechnology company based in Kerrville, Texas, dedicated to developing innovative cancer therapies that utilize Light-Activated Intracellular Acidosis (LAIA). Founded in 2015 by Matt Gdovin and Greg Espenhover, the company aims to enhance the quality of life for cancer patients and healthcare professionals by providing effective treatments that minimize side effects. Vitanova's approach leverages energy-based techniques that activate cancer-specific intracellular acidosis through targeted wavelengths of light and nanoparticles, which are designed to selectively target cancer cells using antibody or antigen conjugation. This strategy not only offers a cost-effective solution for cancer therapy but also seeks to improve patient outcomes in a transformative manner.

Intact Therapeutics is a biotechnology company based in Belmont, California, founded in 2015. The company focuses on developing a thermosensitive drug delivery platform, specifically smart gels designed for the treatment of gastrointestinal disorders, including ulcerative colitis. Their proprietary gel technology remains in a liquid state at room temperature, transforming into a mucoadhesive gel at body temperature. This innovative approach allows for targeted drug delivery, providing localized concentrations of medication while minimizing systemic exposure. The gel's design enhances drug retention, efficacy, and patient comfort, offering a painless healing option for individuals suffering from inflammatory bowel diseases.

Koya Medical, Inc., founded in 2018 and based in Oakland, California, specializes in developing innovative therapeutic devices aimed at treating cancer-related chronic lymphedema and various venous diseases. The company focuses on creating wearable technology that delivers active compression therapy, which is designed to enhance movement and mobility for patients. Koya Medical's approach offers a personalized alternative to traditional compression methods, utilizing a sensor-based closed-loop system to provide tailored compression patterns. This technology addresses the needs of patients suffering from conditions such as lymphedema, chronic edema, and chronic venous insufficiency, thereby improving their quality of care and overall treatment outcomes.

VeraMorph is a pharmaceutical company established in 2017 and located in Mansfield, Massachusetts. The company specializes in developing an innovative oral drug delivery technology centered around proprietary oral hydrogel tablets. This technology is designed to enhance drug stability, expedite dissolution rates, and maintain prolonged high saturation levels, allowing for higher drug loading compared to existing formulations. By providing contract manufacturing and formulation services, VeraMorph aims to assist pharmaceutical companies in improving the performance of their products while reducing both costs and the time required to bring new drugs to market.

Kaden Health, Inc. is a New York-based company that specializes in providing virtual treatment services for individuals with opioid use disorder. Founded in 2018 and originally named Thrivee, Inc., the company rebranded in October 2020 to reflect its focus on humanizing addiction recovery. Kaden Health operates an online remote healthcare platform that connects patients with healthcare providers and personalized advocates, emphasizing the importance of strong relationships in the recovery process. The platform facilitates access to medication-assisted treatment and utilizes proprietary technology to enhance behavioral health, making proven treatments more accessible for those seeking help with opioid addiction.

Obsidio, Inc. is a medical device company founded in 2018 and based in Solana Beach, California. The company specializes in developing shear-thinning hydrogel biomaterial technology, which is used to manufacture therapeutic devices and universal gel embolization materials. This technology allows for minimally invasive procedures to inject embolic materials through catheters, effectively stopping undesirable blood flow in vessels throughout the body. Obsidio's products are applicable in various medical scenarios, including the treatment of hemorrhages, aneurysms, and tumors, as well as managing conditions related to coagulopathy. By focusing on interventional radiology and oncology, Obsidio aims to provide precise and durable solutions for vascular occlusion.

Impleo Medical focuses on developing minimally invasive medical devices, specifically an outpatient injection therapy platform aimed at treating gastroesophageal reflux disease (GERD). This innovative therapy involves a one-time outpatient procedure performed under sedation, delivering lasting relief from acid reflux symptoms. By providing an alternative to both long-term medication and invasive surgical options, Impleo Medical's treatment addresses a significant gap in GERD management, allowing physicians to effectively prevent the flow of gastric acid into the esophagus.

Ichosia Biotechnology, founded in 2019 and based in Worcester, Massachusetts, focuses on the development of derived red blood cells by leveraging natural genetic processes. The company has created a platform that genetically engineers human stem cells to produce red blood cells, aiming to support healthcare providers and patients in need. This innovative approach enables the provision of blood on demand for patients at risk, addressing critical shortages and improving patient care in medical settings.

Unlocked Labs specializes in developing innovative probiotics aimed at addressing chronic health conditions by utilizing genetically optimized microbial strains. The company focuses on activating dormant microbial abilities to effectively digest compounds that can lead to health issues. Their first product targets the risk of kidney stones by breaking down stone-forming compounds derived from healthy foods like leafy vegetables. Unlocked Labs employs alternative regulatory pathways to expedite the availability of safe and effective probiotic solutions for consumers. By harnessing the natural detoxifying capabilities of symbiotic microbes, their products aim to reduce acid levels in the body, making them both affordable and accessible to a wide audience.

Erisyon Inc. is a biotechnology company based in Austin, Texas, founded in 2018. It specializes in the research and development of a novel single molecule protein sequencer, which has the potential to revolutionize disease detection, treatment, and monitoring. The technology has diverse applications across several fields, including oncology for personalized cancer therapies, diagnostics for disease discovery, plant science for enhancing crop growth, drug development for creating new pharmaceuticals, and industrial biology. By leveraging over a decade of research from the University of Texas at Austin's Center for Systems and Synthetic Biology, Erisyon aims to contribute to advancements that promote health, safety, and abundance in society.

Oscillo Biosciences focuses on developing innovative pharmacological treatments for Alzheimer's disease and related disorders. The company has conducted studies to assess the impact of music and multisensory stimulation on brain activity in adults. Oscillo Biosciences creates a prescription medical device and a digital therapeutic that work in tandem to restore healthy brain function in patients experiencing mild cognitive impairment and Alzheimer's disease. Their approach is grounded in the understanding that brain rhythms essential for memory and cognition are disrupted in these patients. Additionally, Oscillo Biosciences develops human-centered technologies aimed at rehabilitating individuals with language, cognitive, and motor impairments, utilizing rhythmic behaviors associated with speech, music, and movement to create effective therapies.

A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.

Ferric Contrast is a developer of diagnostic tools focused on creating safe magnetic resonance imaging (MRI) contrast agents. The company specializes in iron-based contrast agents that facilitate the production of high-quality MRI images of the brain, vasculature, liver, and kidneys. Additionally, these agents are designed to aid in the detection of cancerous tumors, offering medical professionals a versatile solution for effective patient diagnosis and treatment. By prioritizing safety and efficacy, Ferric Contrast aims to enhance imaging capabilities in clinical settings.

Cordance Medical is a medical device company that develops radical therapy for a variety of CNS pathology, including primary and metastatic cancer, Alzheimer's, and Parkinson's diseases.

LEAH Labs provides Car T cells for curing B-cell lymphoma cancer in dogs. Scientists at LEAH Labs use precision gene editing to reprogram T immune cells with Chimeric Antigen Receptors (CAR) in order to create CAR T cells that seek out, specifically recognize, and destroy B cell lymphoma without the off-target side effects that come with chemotherapy.

Opticyte, Inc. is a medical device company based in Seattle, WA, focused on developing innovative technology for monitoring oxygen levels in cells to prevent organ failure. Founded in 2016 as a spinoff from the University of Washington, Opticyte is creating the first Cell O2 Monitor, a noninvasive oximeter that utilizes advanced algorithms and optical spectroscopy. This device is designed to measure oxygen concentration within cells, facilitating early detection of critical conditions such as shock, sepsis, hemorrhage, and cardiac dysfunction. By enabling clinicians to make timely treatment decisions, Opticyte aims to reduce the risk of multiple organ failure and improve patient outcomes. The company comprises a team with significant expertise in engineering, regulatory affairs, and communications, dedicated to bringing this essential medical technology to market.

Akanocure Pharmaceuticals is a biotechnology company focused on developing innovative anti-cancer chemotherapeutic drugs aimed at treating various forms of cancer. The company is dedicated to finding therapeutic approaches that effectively block the metastatic processes responsible for 90% of cancer-related deaths. By harnessing the expertise of its team throughout the drug discovery and development phases, Akanocure aims to create novel small molecules derived from natural resources. These bio-targeted therapeutics are designed not only to combat cancer but also to alleviate the side effects associated with chemotherapy and other cancer treatments, ultimately improving the quality of life for patients.

Precision Microwave specializes in the development of microwave energy-based tools and technology aimed at providing minimally invasive treatments for cancer and other tumors. The company's innovative approach involves the use of needle-like applicators embedded with miniature microwave antennas, which can be inserted directly into tumors to deliver targeted heat and effectively destroy cancerous cells. This technology is designed to assist physicians in offering advanced medical treatments, ultimately improving healthcare outcomes for patients suffering from cancer. An online inquiry form is available on the company's website for interested parties seeking more information.

Haima Therapeutics is a pre-clinical stage biotechnology company dedicated to developing bio-inspired therapies for the treatment of bleeding and various blood-related disorders. The company focuses on creating platelet-inspired therapeutics that address conditions where platelets are crucial, such as thrombosis, inflammation, and cancer. Its innovative technology involves fully-synthetic nanoparticle-based hemostatic solutions designed to mitigate bleeding by enhancing the body's natural clotting mechanisms at the injury site. This approach aims to facilitate faster recovery for patients undergoing traumatic injuries, surgeries, and other blood-related health issues.

Neurosonics Medical specializes in ultrasound devices for brain tumor ablation. The company was founded in 2018 and is headquartered in Baltimore, Maryland.

Averto Medical is a manufacturer of medical devices focused on addressing gastrointestinal diseases. The company specializes in developing innovative solutions designed to facilitate minimally invasive colorectal tumor removal, which aims to reduce the need for multiple surgical procedures and associated complications. By providing effective medical care options for patients suffering from gastrointestinal disorders, Averto Medical seeks to improve patient outcomes and streamline treatment processes in this critical area of healthcare.